Jonathan Pachter
Chief Scientific Officer Verastem. inc
Dr. Pachter has over 30 years of experience leading discovery and translational research for small molecule and monoclonal antibody anti-cancer therapeutics. He joined Verastem in 2011, and has led research targeting RAS-dependent cancers and liquid tumors with the company’s clinical stage RAF/MEK, FAK and KRAS G12D inhibitors. He was previously Head of Cancer Biology at OSI Pharmaceuticals where his team focused on kinase inhibitors, including erlotinib, for treatment of solid tumors. Prior to OSI, Dr. Pachter held positions of increasing responsibility at Schering-Plough, progressing 3 agents into development and making key contributions to the regulatory approval of temozolomide. Dr. Pachter did postdoctoral work at Yale University School of Medicine, holds a Ph.D. from Baylor College of Medicine, and is an author of over 85 publications.
Seminars
- Developing a mechanistically differentiated KRAS G12D inhibitor designed to achieve selective pathway suppression while addressing limitations observed with firstgeneration KRAS targeting approaches
- Exploring rational combination strategies that enhance antitumor activity and delay resistance through complementary pathway modulation
- Demonstrating compelling preclinical efficacy and translational insights supporting clinical advancement in KRAS G12D-driven tumors
